22,196 Shares in Avanos Medical, Inc. $AVNS Acquired by Cove Street Capital LLC

Cove Street Capital LLC acquired a new position in Avanos Medical, Inc. (NYSE:AVNS) in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 22,196 shares of the company’s stock, valued at approximately $318,000.

Several other hedge funds also recently added to or reduced their stakes in the business. T. Rowe Price Investment Management Inc. grew its position in Avanos Medical by 24.8% in the first quarter. T. Rowe Price Investment Management Inc. now owns 3,757,576 shares of the company’s stock worth $53,847,000 after acquiring an additional 746,264 shares during the period. Armistice Capital LLC purchased a new position in Avanos Medical in the first quarter worth approximately $28,660,000. Brown Advisory Inc. grew its position in Avanos Medical by 1.4% in the first quarter. Brown Advisory Inc. now owns 1,931,163 shares of the company’s stock worth $27,674,000 after acquiring an additional 26,069 shares during the period. Charles Schwab Investment Management Inc. grew its position in Avanos Medical by 32.3% in the first quarter. Charles Schwab Investment Management Inc. now owns 608,635 shares of the company’s stock worth $8,722,000 after acquiring an additional 148,619 shares during the period. Finally, Northern Trust Corp grew its position in Avanos Medical by 4.9% in the fourth quarter. Northern Trust Corp now owns 526,763 shares of the company’s stock worth $8,386,000 after acquiring an additional 24,720 shares during the period. 95.17% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research analysts recently weighed in on AVNS shares. Wall Street Zen lowered Avanos Medical from a “strong-buy” rating to a “buy” rating in a research report on Saturday, August 9th. Zacks Research upgraded Avanos Medical to a “hold” rating in a research report on Tuesday, August 12th. One analyst has rated the stock with a Hold rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Hold”.

Insider Activity at Avanos Medical

In other news, Director Gary Blackford purchased 40,000 shares of the stock in a transaction dated Wednesday, August 13th. The stock was acquired at an average cost of $10.99 per share, for a total transaction of $439,600.00. Following the completion of the transaction, the director directly owned 40,000 shares in the company, valued at approximately $439,600. This represents a ∞ increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this link. 2.64% of the stock is currently owned by corporate insiders.

Avanos Medical Trading Up 3.1%

AVNS opened at $12.34 on Thursday. Avanos Medical, Inc. has a 52 week low of $9.30 and a 52 week high of $25.36. The business has a fifty day simple moving average of $11.61 and a 200-day simple moving average of $12.76. The firm has a market cap of $572.34 million, a P/E ratio of -1.22 and a beta of 1.12. The company has a quick ratio of 1.58, a current ratio of 2.64 and a debt-to-equity ratio of 0.12.

Avanos Medical (NYSE:AVNS) last released its quarterly earnings results on Tuesday, August 5th. The company reported $0.17 EPS for the quarter, missing the consensus estimate of $0.18 by ($0.01). Avanos Medical had a positive return on equity of 6.16% and a negative net margin of 66.89%.The firm had revenue of $175.00 million for the quarter, compared to analysts’ expectations of $165.50 million. During the same quarter in the prior year, the business earned $0.34 earnings per share. Avanos Medical has set its FY 2025 guidance at 0.750-0.950 EPS. On average, equities analysts expect that Avanos Medical, Inc. will post 1.32 earnings per share for the current year.

Avanos Medical Profile

Avanos Medical, Inc, a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions.